FOS and osteosarcoma: Experimental evidence has shown that the JNK inhibitor SP600125 significantly reduces the transcriptional impact of AP‐1, thereby decreasing the migration of osteosarcoma cells163 Metformin increases the ROS‐mediated JNK/c‐Jun signal pathway to induce apoptosis in osteosarcoma.